Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Products under Development by Stage of Development | 8 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Products under Development by Therapy Area | 9 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Products under Development by Indication | 10 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Products under Development by Companies | 13 | 2 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Companies Involved in Therapeutics Development | 20 | 8 |
| Akebia Therapeutics, Inc. | 20 | 1 |
| Bayer AG | 21 | 1 |
| Daiichi Sankyo Company, Limited | 22 | 1 |
| FibroGen, Inc. | 23 | 1 |
| GlaxoSmithKline Plc | 24 | 1 |
| Japan Tobacco Inc. | 25 | 1 |
| Merck &Co., Inc. | 26 | 1 |
| Sigmoid Pharma Limited | 27 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Drug Profiles | 28 | 26 |
| AKB-6899 Drug Profile | 28 | 1 |
| daprodustat Drug Profile | 29 | 2 |
| dimethyloxalylglycine Drug Profile | 31 | 1 |
| DS-1093 Drug Profile | 32 | 1 |
| FG-2216 Drug Profile | 33 | 2 |
| FG-4497 Drug Profile | 35 | 1 |
| FG-6874 Drug Profile | 36 | 1 |
| FG-8205 Drug Profile | 37 | 1 |
| JTZ-951 Drug Profile | 38 | 1 |
| molidustat Drug Profile | 39 | 2 |
| roxadustat Drug Profile | 41 | 6 |
| Small Molecules to Inhibit Prolyl Hydroxylase for Anemia Drug Profile | 47 | 1 |
| vadadustat Drug Profile | 48 | 6 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Dormant Projects | 54 | 1 |
| Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Featured News &Press Releases | 55 | 14 |
| Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease | 55 | 1 |
| Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients | 56 | 1 |
| Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease | 56 | 1 |
| Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan | 57 | 1 |
| Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment | 58 | 1 |
| May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction | 59 | 1 |
| May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat | 59 | 1 |
| Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings | 60 | 1 |
| Apr 20, 2016: Promising Phase 2 Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis | 61 | 1 |
| Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat | 62 | 1 |
| Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease | 62 | 2 |
| Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program | 64 | 1 |
| Nov 07, 2015: Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting | 65 | 1 |
| Nov 03, 2015: FibroGen to Present Roxadustat Clinical Data in Four Presentations at American Society of Nephrology - Kidney Week 2015 | 66 | 1 |
| Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting | 67 | 2 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |
